R.K.

“There are a few questions from me, but hopefully I could go one at a time. Starting off on EVX-01, obviously, it was exciting to see yesterday's news from the Merck-Moderno collaboration because it validates, you know, the program that you have been working on for a while now.”

“This is a question thinking about community oncologists who would also be an important piece of the commercial structure for you folks. So with no FDA-approved, you know, PIC3CA companion diagnostic available, you know, how do you see a community oncologist identifying the wild-type patients at launch?”

“I have a couple of them since most of my questions have been answered.”

“Regarding the DOD procurement that you're expecting, Since I believe this particular funding got initiated sometime in February, early February, and as we know the budget year ends in September, do you have any insight into when some of this procurement could happen or is do you think this could bleed into 2027 budget…”

“So a couple of quick questions, you know, the first one being on the biotissue accretion part of it, you know, with biotissue surgical assets generating about $29 million in 2025 and given, And, you know, considering the upfront cost and also you bringing in 20 direct sales folks and integrating them, you know, when…”